CAR-NK for tumor immunotherapy: Clinical transformation and future prospects
Author:
Publisher
Elsevier BV
Subject
Cancer Research,Oncology
Reference75 articles.
1. First-ever CAR T-cell therapy approved,2017
2. FDA approves second CAR T-cell therapy;Cancer Discov.,2018
3. Outcomes of patients with large B-cell lymphomas and progressive disease following CD19-specific CAR T-cell therapy;Chow;Am. J. Hematol.,2019
4. Chimeric antigen receptor-engineered NK-92 cells: an off-the-shelf cellular therapeutic for targeted elimination of cancer cells and induction of protective antitumor immunity;Zhang;Front. Immunol.,2017
5. “Natural” killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype;Kiessling;Eur. J. Immunol.,1975
Cited by 158 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Harnessing the Power of NK Cell Receptor Engineering as a New Prospect in Cancer Immunotherapy;Pharmaceutics;2024-08-29
2. Lipid-Based Nanoparticles Fused with Natural Killer Cell Plasma Membrane Proteins for Triple-Negative Breast Cancer Therapy;Pharmaceutics;2024-08-29
3. CD19 CAR T cells for B cell malignancies: a systematic review and meta-analysis focused on clinical impacts of CAR structural domains, manufacturing conditions, cellular product, doses, patient’s age, and tumor types;BMC Cancer;2024-08-22
4. The basic biology of NK cells and its application in tumor immunotherapy;Frontiers in Immunology;2024-08-16
5. Beyond CAR-T: The rise of CAR-NK cell therapy in asthma immunotherapy;Journal of Translational Medicine;2024-08-05
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3